Cholinesterase inhibitor use and age in the general population [1]

Archives of Neurology

Volumn 63, Issue 1, 2006, Pages 154-155

  Lucca, Ugo ^a   Nobili, Alessandro ^b   Riva, Emma ^b   Tettamanti, Mauro ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG USE; HUMAN; INCIDENCE; LETTER; MINI MENTAL STATE EXAMINATION; POPULATION; PREVALENCE; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DEMENTIA; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE;

EID: 30344456695     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.1.154     Document Type: Letter

References (5)

1. Lucca U, Tediosi F, Tettamanti M. Epidemiologic Dimension and Economic Impact of Dementia in Italy [in Italian]. Milan, Italy: Emme Edizioni; 2001.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122.
3. Martin GM. Frontiers of aging. Science. 2001;294:13.
4. Schoenmaker N, Van Gool WA. The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurol. 2004;3:627-630.
5. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Intl J Geriatr Psychopharmacol. 1998;1(suppl 1):S26-S34.